CCNU-adriamycin therapy in bronchogenic carcinoma

Area of Science:

• Oncology
• Medical Oncology
• Cancer Research

Background:

• Advanced bronchogenic carcinoma presents a significant therapeutic challenge.
• Chemotherapy remains a cornerstone in managing advanced lung cancer.
• Evaluating novel drug combinations is crucial for improving patient outcomes.

Purpose of the Study:

• To assess the efficacy and toxicity of a combination chemotherapy regimen.
• To determine the objective response rate (ORR) in patients with advanced lung cancer.
• To evaluate the impact of this regimen on median survival time (MST).

Main Methods:

• A cohort of 48 patients with advanced bronchogenic carcinoma was enrolled.
• Treatment involved a combination of CCNU (lomustine) and Adriamycin (doxorubicin).
• Objective response rates and median survival times were analyzed across different histological subtypes.

Main Results:

• An overall objective response rate of 38% was observed.
• Response rates varied by histology: epidermoid (8%), adenocarcinoma (33%), large cell (40%), and small cell (63%).
• Median survival times ranged from 18 weeks (epidermoid) to over 30 weeks (small cell), with longer survival associated with objective tumor response.

Conclusions:

• The combination of CCNU and Adriamycin demonstrates activity in advanced lung cancer, particularly in small cell histology.
• The treatment regimen was associated with minimal toxicity and no drug-related deaths.
• Objective tumor response correlates with improved survival, suggesting this combination as a viable option for selected patients.